Huanggang Central Hospital — Huanggang, Hubei

Public research footprint of Huanggang Central Hospital, compiled from the ClinicalTrials.gov public registry.

Registered studies

Active

Recruiting now

Completed

Most-studied conditions

HFRS (Hemorrhagic Fever With Renal Syndrome) · Severe Fever With Thrombocytopenia Syndrome · T2DM (Type 2 Diabetes Mellitus) · Acute Ischemic Stroke

Recently updated registry entries

NCT06415773 — Effects of Berberine Ursodeoxycholate (HTD1801) Versus Dapagliflozin in Patients With… (Completed)
NCT07741448 — Neoadjuvant Gemcitabine Plus Trastuzumab Rezetecan in HER2-positive UTUC (Recruiting)
NCT07693959 — Neoadjuvant RC48 Plus Gemcitabine in HER2-Expressing MIBC (Recruiting)

7 more recent registry entries at this facility

Enter your work email to view the full list.

I’d also like to receive occasional marketing emails from Eichor for research sites (optional — unsubscribe anytime).

Work at Huanggang Central Hospital?

Verify and correct how your facility appears in public registry records — free.

Verify this profile →

Compiled from public registry records (ClinicalTrials.gov) as of August 03, 2026. Counts reflect how this facility appears in registry listings; name variants may exist and are not combined. This page describes public records only and makes no assessment of any facility.